Source comparison
Head-to-Head Mechanism Comparison Summary
Primary molecular target: BPC-157 → FAK Tyr397 → Src → EGFR/VEGFR2 transactivation. Tβ4 → G-actin LKKTET sequestration → profilin competition → directed lamellipodia extension + ILK-AKT survival. Angiogenesis mechanism: BPC-157 → FAK-Src-VEGFR2 Tyr1175 → PLCγ1
This comparison does not assign a generated winner or score.
- Primary molecular target: BPC-157 → FAK Tyr397 → Src → EGFR/VEGFR2 transactivation. Tβ4 → G-actin LKKTET sequestration → profilin competition → directed lamellipodia extension + ILK-AKT survival.
- Angiogenesis mechanism: BPC-157 → FAK-Src-VEGFR2 Tyr1175 → PLCγ1-PKC-ERK1/2 → endothelial proliferation; tube formation +32-40%. Tβ4 → actin cytoskeletal remodelling + ILK-AKT-eNOS endothelial signalling; tube formation +28-36%. Both comparable magnitude, different molecular route.
- Tenocyte repair: BPC-157 slightly superior biomechanics (load 18.4 vs 16.8N Tβ4); Tβ4 slightly superior SCX tenocyte differentiation. Combined protocol rationale supported.
- Muscle satellite cell: Tβ4 slightly superior SC survival (ILK-AKT anoikis resistance) and M2 macrophage polarisation; BPC-157 comparable. Both superior to vehicle.
- Gut/organ-specific (BPC-157 unique): TJ barrier restoration (ZO-1/occludin/claudin-2, ID 77523), renal AKI protection (ID 77528), endometriosis pain (COX-2/PGE2/NGF, ID 77525), stroke BBB (MMP-9/claudin-5, ID 77529) — none of these have Tβ4 equivalents.
- Cardiac post-MI (Tβ4 unique): Epicardial progenitor activation, post-MI scar reduction, ILK-cardioprotection (ID 77527) — BPC-157 lacks this specific post-MI epicardial mechanism.
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.